These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 21623691)
1. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Spurgeon SE; Pindyck T; Okada C; Chen Y; Chen Z; Mater E; Abbi K; Epner EM Leuk Lymphoma; 2011 Aug; 52(8):1488-94. PubMed ID: 21623691 [TBL] [Abstract][Full Text] [Related]
2. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Inwards DJ; Fishkin PA; Hillman DW; Brown DW; Ansell SM; Kurtin PJ; Fonseca R; Morton RF; Veeder MH; Witzig TE Cancer; 2008 Jul; 113(1):108-16. PubMed ID: 18470909 [TBL] [Abstract][Full Text] [Related]
3. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas. Puvvada SD; Guillen-Rodriguez J; Kumar A; Inclán L; Heard K; Rivera XI; Anwer F; Schatz JH; Mahadevan D; Persky DO Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):58-64. PubMed ID: 29056470 [TBL] [Abstract][Full Text] [Related]
4. Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Inwards DJ; Fishkin PA; LaPlant BR; Drake MT; Kurtin PJ; Nikcevich DA; Wender DB; Lair BS; Witzig TE Ann Oncol; 2014 Oct; 25(10):2020-2024. PubMed ID: 25057177 [TBL] [Abstract][Full Text] [Related]
5. Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma. Hosein PJ; Sandoval-Sus JD; Goodman D; Arteaga AG; Reis I; Hoffman J; Stefanovic A; Rosenblatt JD; Lossos IS Am J Hematol; 2015 Jun; 90(6):E111-6. PubMed ID: 25737247 [TBL] [Abstract][Full Text] [Related]
6. Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma. Spurgeon SE; Sharma K; Claxton DF; Ehmann C; Pu J; Shimko S; Stewart A; Subbiah N; Palmbach G; LeBlanc F; Latour E; Chen Y; Mori M; Hasanali Z; Epner EM Br J Haematol; 2019 Sep; 186(6):845-854. PubMed ID: 31177537 [TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. Salek D; Vesela P; Boudova L; Janikova A; Klener P; Vokurka S; Jankovska M; Pytlik R; Belada D; Pirnos J; Moulis M; Kodet R; Michal M; Janousova E; Muzik J; Mayer J; Trněný M Leuk Lymphoma; 2014 Apr; 55(4):802-10. PubMed ID: 23772666 [TBL] [Abstract][Full Text] [Related]
8. The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma. Ying ZT; Zheng W; Wang XP; Xie Y; Tu MF; Lin NJ; Ping LY; Liu WP; Deng LJ; Zhang C; Zhu J; Song YQ Chin J Cancer; 2012 Jul; 31(7):348-53. PubMed ID: 22704490 [TBL] [Abstract][Full Text] [Related]
9. The epigenetics of mantle cell lymphoma. Yu M; Epner E Curr Treat Options Oncol; 2007 Oct; 8(5):375-81. PubMed ID: 18214689 [TBL] [Abstract][Full Text] [Related]
10. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442 [TBL] [Abstract][Full Text] [Related]
11. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Sachanas S; Pangalis GA; Vassilakopoulos TP; Korkolopoulou P; Kontopidou FN; Athanasoulia M; Yiakoumis X; Kalpadakis C; Georgiou G; Masouridis S; Moschogiannis M; Tsirkinidis P; Pappis V; Kokoris SI; Siakantaris MP; Panayiotidis P; Angelopoulou MK Leuk Lymphoma; 2011 Mar; 52(3):387-93. PubMed ID: 21133713 [TBL] [Abstract][Full Text] [Related]
12. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Merli F; Luminari S; Ilariucci F; Petrini M; Visco C; Ambrosetti A; Stelitano C; Caracciolo F; Di Renzo N; Angrilli F; Carella AM; Capodanno I; Barbolini E; Galimberti S; Federico M Br J Haematol; 2012 Feb; 156(3):346-53. PubMed ID: 22145911 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390 [TBL] [Abstract][Full Text] [Related]
14. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. Rummel MJ; Chow KU; Karakas T; Jäger E; Mezger J; von Grünhagen U; Schalk KP; Burkhard O; Hansmann ML; Ritzel H; Bergmann L; Hoelzer D; Mitrou PS Eur J Cancer; 2002 Sep; 38(13):1739-46. PubMed ID: 12175690 [TBL] [Abstract][Full Text] [Related]
15. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M; Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757 [TBL] [Abstract][Full Text] [Related]
16. High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma. Lossos IS; Hosein PJ; Morgensztern D; Coleman F; Escalón MP; Byrne GE; Rosenblatt JD; Walker GR Leuk Lymphoma; 2010 Mar; 51(3):406-14. PubMed ID: 20038221 [TBL] [Abstract][Full Text] [Related]
17. [Cytarabine and hematopoietic cell transplantation for mantle cell lymphoma. Analysis of 20 patients]. Campbell J; Hurtado S; Kutz C; Soto K; Ernst D Rev Med Chil; 2019; 147(1):9-17. PubMed ID: 30848759 [TBL] [Abstract][Full Text] [Related]
18. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Till BG; Li H; Bernstein SH; Fisher RI; Burack WR; Rimsza LM; Floyd JD; DaSilva MA; Moore DF; Pozdnyakova O; Smith SM; LeBlanc M; Friedberg JW Br J Haematol; 2016 Jan; 172(2):208-18. PubMed ID: 26492567 [TBL] [Abstract][Full Text] [Related]
19. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward? Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476 [TBL] [Abstract][Full Text] [Related]
20. [Clinical analysis of 140 cases of mantle cell lymphoma]. Hu MW; Lou YJ; Yang M; Wang HF; Wang L; Jin J Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):390-395. PubMed ID: 29860768 [No Abstract] [Full Text] [Related] [Next] [New Search]